Tocilizumab long-term extension trial in patients with adult onset still - Tocilizumab long-term extension trial in patients with adult onset still

Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine0 个研究点目标入组 34 人开始时间: 2015年7月24日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) Patients who have not been enrolled within 3 months since last observation in KCCR-D002 clinical trial 2)Patients having received following therapy before starting treatment since last observation in KCCR-D002 clinical trial (1) Tocilizumab , Inflixmab, Golimumab, Adalimumab, Apatacept, Leflunomide Certolizumab pegol,Etanercept and these biosimilar (2) DMARDs or immune-suppressing drug (3) Cell depletion therapy (4) Surgical treatment excluding local procedures (dental extraction or ophthalmologic laser surgery etc. (5) Plasma exchange therapy (6) Tocilizumab 3) Patients with serious drug allergy for Tocilizumab in KCCR-D002 clinical trials 4) Patient with current and past history of following disease and diagnosed as inapplicable to this study by a doctor, cardiovascular disease, hematologic/ hematopoietic disease, respiratory disease, neurological/muscular disorder, endocrine disease, renal/urological disease or gastroenterological disorder 5) Patients with infection within 4 weeks before initial administration in this study and diagnosed as inapplicable to this study by a doctor 6) Expectant mother, mother with breast-feeding, patient who have possibility of pregnancy or hope to be pregnant 7) Others not applicable person determined by a doctor

发起方

Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine